Nsclc 공개
[search 0]

Download the App!

show episodes
 
Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking. In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC. This non-certified educ ...
 
Loading …
show series
 
Host: Paul P. Doghramji, MD, FAAFP Guest: Edward S. Kim, MD Thanks to recent research, we can now use a non-small cell cancer patient’s cancer type and genomic makeup to create targeted treatment plans. Joining Dr. Paul Doghramji to share what that approach looks like in practice is Dr. Edward Kim, the Chair of Solid Tumor Oncology and Investigatio…
 
Guest: Edward S. Kim, MD When looking at the non-small cell lung cancer landscape, we’re now seeing the emergence of several genetic markers that may have therapies linked to them, and one of those markers is the RET fusion that exists. Join Dr. Edward Kim as he gets us caught up on the investigational therapies targeting RET-mutated non-small cell…
 
Guest: Michael R. Shafique, MD The therapies that have been approved for non-small cell lung cancer stimulate the immune system to attack cancer cells… But what happens when they do too good a job of that and stimulate the immune system to inflame other parts of the body as well? Dr. Michael Shafique from the Moffitt Cancer Center breaks down the m…
 
Guest: Michael R. Shafique, MD After many decades of trying to improve the outcomes of patients with advanced non-small cell lung cancer, we may finally have the therapeutic approach that achieves that goal: maintenance therapy. Join Dr. Michael Shafique, an Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center, as he reviews the da…
 
Host: Paul Doghramji, MD Guest: Tony Y. Hu, PhD One of the biggest blindspots for those who care for patients with lung cancer is not knowing whose disease is going to metastasize quickly and who, by extension, would benefit from the most aggressive treatments up front. But the entrance of better detection methods, such as biomarkers and assay test…
 
Host: Paul Doghramji, MD Guest: Tony Y. Hu, PhD Since treatment outcomes vary greatly between lung cancer patients—even among those who are diagnosed at the same stages of disease—much research has been devoted to finding biomarkers that identify patients who are most likely to develop metastatic disease. Here to walk us through a promising line of…
 
Guest: Amit Bobby Mahajan, MD, FCCP, DAABIP Lung cancer is known to be the deadliest and second most common cancer in men and women. Although there currently isn’t a cure, the last decade has shown great improvements and hope for the treatment of non-small cell lung cancer, as Dr. Bobby Mahajan explains.…
 
Guest: Deepa Rangachari, MD With newly approved therapies on the rise, the way we treat non-small cell lung cancer patients with a RET gene rearrangement may be evolving. That’s why it’s so important to test for RET mutations in patients with non-small cell lung cancer, as oncologist Dr. Deepa Rangachari explains.…
 
Guest: Deepa Rangachari, MD Communication is the key to guiding patients with non-small cell lung cancer through testing and treatment, but what exactly does that look like? Dr. Deepa Rangachari, an oncologist at the Beth Israel Deaconess Medical Center, shares strategies to help patients understand these processes and set realistic expectations.…
 
Host: Jennifer Caudle, DO Guest: Deepa Rangachari, MD Survival rates for patients with non-small cell lung cancer have notably improved thanks to the development of targeted therapies and immunotherapies. With these recent advancements on the forefront, Dr. Deepa Rangachari joins Dr. Jennifer Caudle to discuss the KEYNOTE-189 study and how it could…
 
Guest: Deepa Rangachari, MD Living with non-small cell lung cancer means living with a daily burden of symptoms like fatigue, decreased appetite, and shortness of breath. Dr. Deepa Rangachari, an oncologist at Harvard’s Beth Israel Deaconess Medical Center, expresses the importance of finding therapeutic strategies to help patients manage symptoms.…
 
Guest: Joshua M. Bauml, MD When a patient presents with non-small cell lung cancer, one question that comes up is: Could this patient have a RET fusion? Here to explore how we can answer that question is Dr. Joshua Bauml, medical oncologist and Assistant Professor at the University of Pennsylvania’s Perelman School of Medicine.…
 
Guest: Joshua M. Bauml, MD Now that there are more targeted therapies available for metastatic non-small cell lung cancer, what are the best practices for evaluating our patients? Dr. Joshua Bauml elaborates on the opportunities and challenges faced when testing for oncogenic drivers in non-small cell lung cancer.…
 
Guest: Joshua M. Bauml, MD When a patient with non-small cell lung cancer harboring a molecular driver alteration develops resistance to their therapy, it’s important that we identify what the source of that resistance is, as Dr. Joshua Bauml from the University of Pennsylvania explains.
 
Host: Mario R. Nacinovich, Jr., MSc Guest: Lyudmila Bazhenova, MD Targeted therapies for oncogenic mutations in non-small cell lung cancer have shown a lot of potential when it comes to tailoring systemic treatment strategies to more specific tumor types and mutations. But just like any other therapeutic approach, it’s not without its challenges. T…
 
Guest: Joshua M. Bauml, MD The COVID-19 pandemic has presented a unique and difficult problem for clinicians and patients alike. Here to share how he’s continuing treatment for his patients with non-small cell lung cancer in the era of COVID-19 is Dr. Joshua Bauml, a medical oncologist and Assistant Professor at the Perelman School of Medicine at t…
 
Host: Mario R. Nacinovich, Jr., MSc Guest: Gregory J Kubicek, MD What treatments and technologies are on the horizon for our patients with non-small cell lung cancer? Joining Mario Nacinovich to give us a look at what’s ahead is Dr. Gregory Kubicek, staff radiation oncologist at the MD Anderson Cooper Cancer Center.…
 
Guest: Jacob Sands, MD Take a deep dive into the data from a recent clinical trial exploring next generation sequencing in lung squamous cell carcinoma with Dr. Jacob Sands, a thoracic medical oncologist at the Dana-Farber Cancer Institute and an Instructor of Medicine at Harvard Medical School.
 
Guest: Jacob Sands, MD Although a lung cancer diagnosis can take a heavy toll on a patient’s mental and emotional well-being, there are counseling strategies you can use to better communicate with your patients and to ease their fears. Here to share the strategies he uses to help his patients cope with a lung cancer diagnosis is Dr. Jacob Sands, a …
 
Guest: Jonathan Riess, MD, MS After beginning treatment for non-small cell lung cancer, it’s important to think about how a patient's body reacts. Tune in as Associate Professor of Oncology and Hematology at the UC Davis Medical Center Dr. Jonathan Riess discusses his top-of-mind considerations for managing toxicities throughout the care course as …
 
Guest: Jonathan Riess, MD, MS When treating patients with non-small cell lung cancer, their physical, mental, and emotional health need to be considered. That’s why Dr. Jonathan Riess, Associate Professor of Oncology and Hematology at the UC Davis Medical Center, is here to explain how he approaches caring for patients with non-small cell lung canc…
 
Host: Mario R. Nacinovich, Jr., MSc Guest: Jonathan Riess, MD, MS Here to explain how our refined understandings of driver mutations, immune properties, and tumor microenvironments have changed the way we think about combination therapies, their benefits and limitations, and what’s on the horizon is Dr. Jonathan Riess, Associate Professor of Oncolo…
 
Host: Mario R. Nacinovich, Jr., MSc Guest: Michael R. Shafique, MD Testing for the biomarker PD-L1 can offer clinicians direction for their treatment approach to non-small cell lung cancer, and here to offer insights on therapeutic approaches for patients with high PD-L1 expression is Dr. Michael Shafique, Assistant Professor of Thoracic Oncology a…
 
Guest: Michael R. Shafique, MD Tune in as Dr. Michael Shafique from the Moffitt Cancer Center explains the KEYNOTE-189 clinical trial, which investigated whether the addition of pembrolizumab to standard of care platinum-based chemotherapy would provide some survival benefit to patients with non-small cell lung cancer.…
 
Host: Jennifer Caudle, DO Guest: Michael R. Shafique, MD Although only a small percentage of patients with non-small cell lung cancer have a genetic mutation involving the RET gene, it’s still essential that we know how this specific mutation impacts our diagnostic and treatment approach. That’s why we’re taking a look at this through the lens of a…
 
Host: John J. Russell, MD Guest: Mark Sundermeyer, MD Early diagnosis of non-small cell lung cancer (NSCLC) can increase patients’ rate of survival, and primary care practitioners play an important role in this since they’re oftentimes on the frontlines of care. Here to discuss with Dr. John Russell how primary care practitioners like himself can e…
 
Guest: Christine Bestvina, MD Oncologist Dr. Chistine Bestvina addresses therapeutic and supportive care priorities for patients with progressive metastatic non-small cell lung cancer. Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for…
 
Guest: Christine Bestvina, MD Even in early-stage disease, the recurrence rate for non-small cell lung cancer can be as high as 30 to 50 percent. Hear from oncologist Dr. Christine Bestvina on how she manages patients with recurrent disease. Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produc…
 
Guest: Christine Bestvina, MD Determining how to treat your non-small cell lung cancer patients is a critical part of their care. Joining us to explore treatment modalities for her patients based on their cancer stage is Dr. Christine Bestvina, an oncologist and Assistant Professor of Medicine at the University of Chicago. Closing the Gaps in NSCLC…
 
Host: Jennifer Caudle, DO Guest: Erin Schenk MD, PhD The lingering fear of CT-based screenings delivering false positives has caused many challenges, but that doesn’t mean achieving accurate diagnostic staging with our non-small cell lung cancer patients is impossible. To prove it, Dr. Erin Schenk walks through the steps she takes to determine a pa…
 
Host: Jennifer Caudle, DO Guest: Erin Schenk MD, PhD Through prevention recommendations and various diagnostic tools, the ability to detect non-small cell lung cancer (NSCLC) early and, by extension, dramatically improve a patient’s quality of life is now achievable. And here to walk Dr. Jennifer Caudle through all of that is Dr. Erin Schenk, an As…
 
Loading …

빠른 참조 가이드

Google login Twitter login Classic login